1. Home
  2. MGF vs ATOS Comparison

MGF vs ATOS Comparison

Compare MGF & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MFS Government Markets Income Trust

MGF

MFS Government Markets Income Trust

HOLD

Current Price

$2.92

Market Cap

99.1M

Sector

Finance

ML Signal

HOLD

Logo Atossa Therapeutics Inc.

ATOS

Atossa Therapeutics Inc.

HOLD

Current Price

$4.83

Market Cap

36.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MGF
ATOS
Founded
1987
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
99.1M
36.2M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
MGF
ATOS
Price
$2.92
$4.83
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$31.67
AVG Volume (30 Days)
70.9K
187.4K
Earning Date
01-01-0001
04-20-2026
Dividend Yield
7.64%
N/A
EPS Growth
N/A
16.67
EPS
N/A
N/A
Revenue
N/A
$1,758.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.93
$0.53
52 Week High
$3.17
$7.56

Technical Indicators

Market Signals
Indicator
MGF
ATOS
Relative Strength Index (RSI) 30.74 67.97
Support Level N/A $0.69
Resistance Level $3.12 $7.56
Average True Range (ATR) 0.03 0.39
MACD -0.01 -0.10
Stochastic Oscillator 6.67 86.09

Price Performance

Historical Comparison
MGF
ATOS

About MGF MFS Government Markets Income Trust

MFS Government Markets Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to seek high current income. The fund invests a majority of the net assets, including borrowings for investment purposes, in U.S. and foreign government securities. The company invest various sectors like U.S. Treasury Securities, Mortgage-Backed Securities, Investment Grade Corporates, Municipal Bonds, Non-U.S. Government Bonds, etc, out of which maximum revenue is gained from U.S. Treasury Securities.

About ATOS Atossa Therapeutics Inc.

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Share on Social Networks: